10.26

2.90% -0.26

Intellia Therapeutics Inc (NTLA)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$10.52

Offen:

$10.98

24-Stunden-Volumen:

1.69M

Relative Volume:

0.25

Marktkapitalisierung:

$1.19B

Einnahmen:

$52.86M

Nettoeinkommen (Verlust:

$-480.19M

KGV:

-2.1877

EPS:

-4.6899

Netto-Cashflow:

$-421.82M

1W Leistung:

+10.91%

1M Leistung:

+9.84%

6M Leistung:

-15.79%

1J Leistung:

-15.02%

1-Tages-Spanne:

$10.14

$10.98

1-Wochen-Bereich:

$9.13

$10.98

52-Wochen-Spanne:

$5.90

$28.25

Intellia Therapeutics Inc Stock (NTLA) Company Profile

Firmenname

Intellia Therapeutics Inc

Sektor

Healthcare (1117)

Branche

Biotechnology (621)

Telefon

857-285-6200

Adresse

40 ERIE STREET, CAMBRIDGE, MA

Mitarbeiter

598

Twitter

@intelliatweets

Nächster Verdiensttermin

2024-11-07

Neueste SEC-Einreichungen

NTLA's Discussions on Twitter

Vergleichen Sie NTLA mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
NTLA Intellia Therapeutics Inc	10.26	1.22B	52.86M	-480.19M	-421.82M	-4.6899
VRTX Vertex Pharmaceuticals Inc	472.17	119.17B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	810.41	84.19B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	407.74	52.77B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	811.40	48.98B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	175.73	36.31B	447.02M	-1.18B	-906.14M	-6.1812

Intellia Therapeutics Inc Stock (NTLA) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-11-12	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-11-11	Herabstufung	Evercore ISI	Outperform → In-line
2025-11-07	Herabstufung	JP Morgan	Neutral → Underweight
2025-10-28	Herabstufung	Bernstein	Outperform → Mkt Perform
2025-10-28	Herabstufung	RBC Capital Mkts	Outperform → Sector Perform
2025-10-27	Herabstufung	Guggenheim	Buy → Neutral
2025-10-27	Herabstufung	William Blair	Outperform → Mkt Perform
2025-10-06	Hochstufung	Citizens JMP	Mkt Perform → Mkt Outperform
2025-04-21	Hochstufung	Wolfe Research	Peer Perform → Outperform
2025-03-05	Eingeleitet	H.C. Wainwright	Buy
2025-02-28	Herabstufung	Goldman	Neutral → Sell
2025-02-28	Herabstufung	JP Morgan	Overweight → Neutral
2025-01-27	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2024-02-23	Herabstufung	Goldman	Buy → Neutral
2024-02-15	Eingeleitet	Wolfe Research	Peer Perform
2023-04-13	Eingeleitet	Canaccord Genuity	Buy
2023-03-21	Eingeleitet	Bernstein	Outperform
2023-03-14	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2023-02-01	Eingeleitet	Cantor Fitzgerald	Overweight
2023-01-24	Hochstufung	Citigroup	Sell → Neutral
2023-01-19	Herabstufung	JMP Securities	Mkt Outperform → Mkt Perform
2022-10-11	Eingeleitet	Morgan Stanley	Overweight
2022-09-21	Eingeleitet	JP Morgan	Overweight
2022-09-01	Eingeleitet	Citigroup	Sell
2022-06-17	Eingeleitet	BMO Capital Markets	Market Perform
2022-06-16	Eingeleitet	BofA Securities	Buy
2022-04-28	Eingeleitet	Credit Suisse	Outperform
2022-02-18	Eingeleitet	William Blair	Outperform
2022-02-07	Hochstufung	Oppenheimer	Perform → Outperform
2022-01-31	Eingeleitet	Cowen	Outperform
2022-01-07	Eingeleitet	Piper Sandler	Overweight
2021-10-05	Eingeleitet	Guggenheim	Buy
2021-09-24	Eingeleitet	Stifel	Buy
2021-06-28	Bestätigt	H.C. Wainwright	Buy
2021-06-11	Eingeleitet	H.C. Wainwright	Buy
2021-05-07	Hochstufung	ROTH Capital	Neutral → Buy
2021-05-04	Eingeleitet	RBC Capital Mkts	Outperform
2021-03-04	Eingeleitet	JMP Securities	Mkt Outperform
2020-12-22	Herabstufung	Robert W. Baird	Outperform → Neutral
2020-10-27	Eingeleitet	Truist	Buy
2020-10-14	Eingeleitet	Wells Fargo	Overweight
2020-09-18	Eingeleitet	Goldman	Buy
2020-02-28	Hochstufung	Oppenheimer	Perform → Outperform
2020-02-14	Herabstufung	Wedbush	Outperform → Neutral
2019-11-01	Hochstufung	Raymond James	Mkt Perform → Outperform
2019-07-09	Eingeleitet	Robert W. Baird	Outperform
2019-06-10	Eingeleitet	ROTH Capital	Neutral
2019-05-03	Hochstufung	Wedbush	Neutral → Outperform
2019-04-12	Eingeleitet	Evercore ISI	Outperform
2018-11-02	Herabstufung	Wedbush	Outperform → Neutral
2018-10-29	Eingeleitet	Credit Suisse	Neutral
2018-09-21	Eingeleitet	Raymond James	Mkt Perform
2018-05-15	Hochstufung	Chardan Capital Markets	Neutral → Buy
2018-03-08	Eingeleitet	JMP Securities	Mkt Outperform
2017-11-01	Bestätigt	Jefferies	Buy
2017-06-22	Fortgesetzt	Jefferies	Buy
2017-03-28	Eingeleitet	Chardan Capital Markets	Buy
2016-08-05	Hochstufung	Jefferies	Hold → Buy

Alle ansehen

Intellia Therapeutics Inc Aktie (NTLA) Neueste Nachrichten

08:13 AM

Intellia Therapeutics, Inc. Updates on Clinical Trials and Regulatory Plans - TradingView — Track All Markets

08:13 AM

04:48 AM

Why Intellia Therapeutics Inc. (38I) stock fits value portfoliosMarket Movement Recap & AI Optimized Trade Strategies - ulpravda.ru

04:48 AM

Jan 08, 2026

CEO Change: Is Intellia Therapeutics Inc. stock a defensive play in 2025Wall Street Watch & Safe Capital Allocation Plans - ulpravda.ru

Jan 08, 2026

How Intellia Therapeutics Inc. stock benefits from global expansion2025 Earnings Surprises & Safe Swing Trade Setups - ulpravda.ru

Jan 08, 2026

Buyback Watch: Can Intellia Therapeutics Inc. stock beat market expectations this quarterWeekly Trend Report & Free Long-Term Investment Growth Plans - ulpravda.ru

Jan 08, 2026

Gene Editing Tools Market to Reach US$ 1,700.05 million by 2033 | - openPR.com

Jan 08, 2026

Jan 07, 2026

Insider Buying: Fred Cohen Acquires 150,000 Shares of Intellia Therapeutics Inc (NTLA) - GuruFocus

Jan 07, 2026

Intellia Therapeutics Insider Sold Shares Worth $314,485, According to a Recent SEC Filing - MarketScreener

Jan 07, 2026

Intellia Therapeutics prepares for JPM Healthcare Conference presentation - Traders Union

Jan 07, 2026

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times

Jan 07, 2026

44th Annual J.P. Morgan Healthcare Conference - Intellia Therapeutics

Jan 07, 2026

Gene editing firm Intellia to share CRISPR work at major health event - Stock Titan

Jan 07, 2026

What analysts say about Intellia Therapeutics Inc 38I stockUtilities Sector Analysis & Identify Ideal Buy Points With Precision - earlytimes.in

Jan 07, 2026

Jan 06, 2026

Why Intellia Therapeutics (NTLA) Is Down After FDA Halts Key CRISPR Trial Over Safety Concerns – And What's Next - Sahm

Jan 06, 2026

BofA Adjusts Price Target on Intellia Therapeutics to $12 From $14, Maintains Neutral Rating - MarketScreener

Jan 06, 2026

Jan 05, 2026

Intellia Stock Declines Around 55% in 3 Months: Here's Why - Finviz

Jan 05, 2026

Intellia Therapeutics reports inducement grants - Medical Buyer

Jan 05, 2026

Jan 03, 2026

We Think Intellia Therapeutics (NASDAQ:NTLA) Needs To Drive Business Growth Carefully - Yahoo Finance

Jan 03, 2026

Jan 02, 2026

Intellia Therapeutics reports inducement grants under Nasdaq Listing Rule 5635(c)(4) - MarketScreener

Jan 02, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView — Track All Markets

Jan 02, 2026

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Jan 02, 2026

Aug Big Picture: Can Intellia Therapeutics Inc stock beat analyst upgradesJuly 2025 Momentum & Daily Technical Stock Forecast Reports - moha.gov.vn

Jan 02, 2026

Trading the Move, Not the Narrative: (NTLA) Edition - Stock Traders Daily

Jan 02, 2026

Jan 01, 2026

Short Squeeze: Is Intellia Therapeutics Inc stock a defensive play in 20252025 Support & Resistance & Real-Time Chart Breakout Alerts - moha.gov.vn

Jan 01, 2026

Dec 31, 2025

Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks - Benzinga

Dec 31, 2025

Cathie Wood shells out $1.3 million on biotech stock - Yahoo Finance

Dec 31, 2025

Cathie Wood Doubles Down on Biotech as 2025 Ends, Offloads Rocket Lab - Yahoo Finance

Dec 31, 2025

Dec 30, 2025

Cathie Wood’s ARK makes strategic stock moves, buys Intellia and sells Roku By Investing.com - Investing.com South Africa

Dec 30, 2025

Cathie Wood’s ARK makes strategic stock moves, buys Intellia and sells Roku - Investing.com

Dec 30, 2025

Intellia Therapeutics Stock Plummets After Adverse Event In Gene Editing Therapy Study: But Retail’s Buying The Dip - MSN

Dec 28, 2025

Voya Investment Management LLC Trims Stock Holdings in Intellia Therapeutics, Inc. $NTLA - MarketBeat

Dec 28, 2025

Dec 27, 2025

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635 - Investing News Network

Dec 27, 2025

Intellia Therapeutics (NASDAQ:NTLA) Cut to "Sell" at Wall Street Zen - MarketBeat

Dec 27, 2025

Dec 24, 2025

Is Intellia Therapeutics Inc 38I a good long term investmentExit Strategy Tips & Download Our Free Trading Blueprint - earlytimes.in

Dec 24, 2025

Dec 21, 2025

Intellia Therapeutics, Inc. (NASDAQ:NTLA) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat

Dec 21, 2025

Dec 20, 2025

Will Intellia Therapeutics Inc. stock remain a Wall Street favoriteTrade Ideas & Long-Term Growth Plans - ulpravda.ru

Dec 20, 2025

Intellia Therapeutics Earnings Notes - Trefis

Dec 20, 2025

Dec 19, 2025

Will Intellia Therapeutics Inc. stock continue dividend increasesJuly 2025 Momentum & Stepwise Trade Signal Implementation - DonanımHaber

Dec 19, 2025

Will Intellia Therapeutics Inc. (38I) stock hit analyst forecastsJuly 2025 Retail & Weekly High Momentum Picks - DonanımHaber

Dec 19, 2025

Is Intellia Therapeutics Inc. stock a top momentum play2025 Stock Rankings & Accurate Buy Signal Alerts - DonanımHaber

Dec 19, 2025